ClinicalTrials.gov record
Active, not recruiting Phase 1 Interventional

A Study of SGN-MesoC2 in Advanced Solid Tumors

ClinicalTrials.gov ID: NCT06466187

Public ClinicalTrials.gov record NCT06466187. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:24 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SGN-MesoC2 in Subjects With Advanced Solid Tumors

Study identification

NCT ID
NCT06466187
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Enrollment
19 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 1, 2024
Primary completion
Apr 30, 2028
Completion
Apr 30, 2029
Last update posted
Jan 11, 2026

2024 – 2029

United States locations

U.S. sites
17
U.S. states
6
U.S. cities
10
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233
The University of Alabama at Birmingham Birmingham Alabama 35249
University of Alabama at Birmingham Birmingham Alabama 35249
The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham Birmingham Alabama 35294
The University of Kansas Clinical Research Center Fairway Kansas 66205
The University of Kansas Hospital Cambridge North Tower A Kansas City Kansas 66160
The University of Kansas Hospital Kansas City Kansas 66160
The University of Kansas Medical Center Medical Office Building Kansas City Kansas 66160
The University of Kansas Cancer Center - Indian Creek Campus Overland Park Kansas 66211
The University of Kansas Cancer Center - Westwood Westwood Kansas 66205
The University of Kansas Cancer Center, Investigational Drug Services Westwood Kansas 66205
Atrium Health Wake Forest Baptist Winston-Salem North Carolina 27157
Sarah Cannon Research Institute - Pharmacy Nashville Tennessee 37203
SCRI Oncology Partners Nashville Tennessee 37203
START San Antonio, LLC San Antonio Texas 78229
START Mountain Region, LLC Salt Lake City Utah 84119
START Mountain Region West Valley City Utah 84119

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06466187, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 11, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06466187 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →